Punit Yadav1, Colin A Hutchison2, Kolitha Basnayake3, Stephanie Stringer1, Mark Jesky1, Lesley Fifer1, Kym Snell4, Jennifer Pinney1, Mark T Drayson5, Mark Cook6, Paul Cockwell1. 1. Department of Renal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. 2. Department of Medicine, Hawke's Bay District Health Board, Hastings, New Zealand. 3. Department of Renal Medicine, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK. 4. Department of Health and Population Sciences, University of Birmingham, Birmingham, UK. 5. Division of Immunity and Infection, University of Birmingham, Birmingham, UK. 6. Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Abstract
OBJECTIVES: The aim of this study was to report the long-term outcomes in patients with multiple myeloma (MM) who receive dialysis treatment for acute kidney injury (AKI) due to myeloma cast nephropathy and subsequently recover renal function. METHODS: Patients presenting with dialysis-dependent AKI secondary to myeloma cast nephropathy and subsequently recovering independent renal function between January 2005 and December 2012 were included in this study. Both renal and haematological parameters were collected at multiple time points as part of routine clinic practice. Factors associated with renal function and overall survival (OS) were determined. RESULTS: Twenty-four patients fulfilled the criteria for inclusion. Mean age was 62.1 years; 75% were male and 75% were of White ethnicity. The median OS was 64.1 months (95% confidence interval [CI] 34.8-93.3). Twenty-three (95.8%) patients remained dialysis-independent until death or end of follow-up; one patient required further haemodialysis treatment during the follow-up period. The independent determinant of worse OS was a known history of chronic kidney disease (CKD) at presentation. Shorter length of time on haemodialysis and higher percentage reduction in clonal serum FLC at day 21 from baseline predicted better excretory renal function (estimated glomerular filtration rate) at 6 months. CONCLUSION: In this series, the large majority of patients with MM and dialysis-dependent AKI secondary to myeloma cast nephropathy who recovered independent renal function had no requirement for further dialysis. Survival following recovery of renal function is good, and early variables are independently associated with survival and future renal function.
OBJECTIVES: The aim of this study was to report the long-term outcomes in patients with multiple myeloma (MM) who receive dialysis treatment for acute kidney injury (AKI) due to myeloma cast nephropathy and subsequently recover renal function. METHODS:Patients presenting with dialysis-dependent AKI secondary to myeloma cast nephropathy and subsequently recovering independent renal function between January 2005 and December 2012 were included in this study. Both renal and haematological parameters were collected at multiple time points as part of routine clinic practice. Factors associated with renal function and overall survival (OS) were determined. RESULTS: Twenty-four patients fulfilled the criteria for inclusion. Mean age was 62.1 years; 75% were male and 75% were of White ethnicity. The median OS was 64.1 months (95% confidence interval [CI] 34.8-93.3). Twenty-three (95.8%) patients remained dialysis-independent until death or end of follow-up; one patient required further haemodialysis treatment during the follow-up period. The independent determinant of worse OS was a known history of chronic kidney disease (CKD) at presentation. Shorter length of time on haemodialysis and higher percentage reduction in clonal serum FLC at day 21 from baseline predicted better excretory renal function (estimated glomerular filtration rate) at 6 months. CONCLUSION: In this series, the large majority of patients with MM and dialysis-dependent AKI secondary to myeloma cast nephropathy who recovered independent renal function had no requirement for further dialysis. Survival following recovery of renal function is good, and early variables are independently associated with survival and future renal function.
Authors: Elizabeth Smyth; Siobhan Glavey; Dario Melotti; Patrick Thornton; Jeremy Sargent; Peter Conlon; Philip Murphy; John Quinn Journal: Ir J Med Sci Date: 2018-12-19 Impact factor: 1.568
Authors: Frank Bridoux; Paul Cockwell; Ilya Glezerman; Victoria Gutgarts; Jonathan J Hogan; Kenar D Jhaveri; Florent Joly; Samih H Nasr; Deirdre Sawinski; Nelson Leung Journal: Nat Rev Nephrol Date: 2021-03-30 Impact factor: 28.314
Authors: Virginie Royal; Nelson Leung; Stéphan Troyanov; Samih H Nasr; Laure Écotière; Richard LeBlanc; Benjamin A Adam; Andrea Angioi; Mariam P Alexander; Anna Maria Asunis; Antonella Barreca; Paola Bianco; Camille Cohen; Maria E Drosou; Huma Fatima; Roberta Fenoglio; François Gougeon; Jean-Michel Goujon; Guillermo A Herrera; Bertrand Knebelmann; Nicola Lepori; Francesca Maletta; Rita Manso; Shveta S Motwani; Antonello Pani; Marion Rabant; Helmut G Rennke; Dario Rocatello; Frida Rosenblum; Paul W Sanders; Afonso Santos; Karina Soto; Banu Sis; Guy Touchard; Christopher P Venner; Frank Bridoux Journal: Blood Date: 2020-05-21 Impact factor: 25.476
Authors: Hans U Gerth; Michele Pohlen; Dennis Görlich; Gerold Thölking; Martin Kropff; Wolfgang E Berdel; Hermann Pavenstädt; Marcus Brand; Philipp Kümpers Journal: PLoS One Date: 2016-05-06 Impact factor: 3.240
Authors: Punit Yadav; Insara Jaffer Sathick; Nelson Leung; Elizabeth E Brown; Mark Cook; Paul W Sanders; Paul Cockwell Journal: Blood Cancer J Date: 2020-03-03 Impact factor: 11.037
Authors: M Victoria Pendón-Ruiz de Mier; Raquel Ojeda; M Antonia Álvarez-Lara; Ana Navas; Corona Alonso; Javier Caballero-Villarraso; Pedro Aljama; Miguel A Álvarez; Sagrario Soriano; Mariano Rodríguez; Alejandro Martín-Malo Journal: BMC Nephrol Date: 2020-06-15 Impact factor: 2.388